AMD supplement protocol — AREDS2 and the rest of the evidence
Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over 60 in high-income countries. The AREDS2 formula has the strongest clinical trial evidence for slowing progression of intermediate AMD to advanced disease — it's the rare supplement intervention with a well-controlled, multi-year, NIH-funded RCT base. Outside that specific population and that specific formula, the evidence base for "eye supplements" gets thinner quickly. The list below stays anchored to what the AREDS, AREDS2, and follow-up trials actually showed.
What actually works in trials
AREDS2 formula
Daily, in two divided doses. Vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg (or 25 mg in newer formulations), copper 2 mg, lutein 10 mg, zeaxanthin 2 mg
The AREDS2 trial (n=4203, 5 years) demonstrated that this combination reduced the 5-year risk of progression from intermediate to advanced AMD by approximately 25%. The original AREDS formulation included beta-carotene; AREDS2 substituted lutein and zeaxanthin because beta-carotene increased lung cancer risk in former smokers. Zinc dose has been a topic of revision — newer formulations frequently use 25 mg rather than 80 mg without losing efficacy, with better tolerability. Indications: intermediate AMD (multiple medium drusen or one large drusen), or advanced AMD in one eye to slow second-eye conversion.
Lutein + Zeaxanthin (standalone, beyond AREDS2)
10 mg lutein + 2 mg zeaxanthin daily; food-source intake from leafy greens supplements this
The macular xanthophylls — lutein and zeaxanthin — are concentrated in the retina and protect against blue-light oxidative damage. Beyond AREDS2 dose, additional supplementation has weaker evidence for AMD-specific endpoints but reasonable evidence for visual performance metrics (contrast sensitivity, glare recovery, photostress) in healthy older adults. Take with a fat-containing meal; both are lipid-soluble. Reasonable as a long-term intake-replacement strategy in people who don't eat much spinach, kale, and similar greens.
Omega-3 (EPA/DHA)
1–2 g EPA+DHA/day combined
The AREDS2 trial added omega-3 to the AREDS formulation and found no additional benefit for AMD progression. Observational studies suggest dietary fish intake associates with lower AMD risk, but supplementation with EPA/DHA on top of AREDS2 has not shown measurable benefit. Reasonable as part of a broader cardiovascular-protective dietary pattern; less clearly beneficial as an "eye supplement" specifically.
The lifestyle base
Several modifiable inputs have stronger evidence than most "eye supplements":
- Smoking cessation — smoking is the largest modifiable risk factor for AMD progression. Stopping is the single highest-yield intervention.
- UV and blue-light protection — sunglasses with UV protection during outdoor activities; the chronic photo-oxidative stress story has reasonable mechanistic support.
- Mediterranean-pattern diet — observational data link Mediterranean dietary patterns (rich in leafy greens, fish, nuts, olive oil) to slower AMD progression in the AREDS cohorts.
- Blood pressure and lipid control — both associate with AMD progression in observational studies; standard cardiovascular risk reduction is reasonable.
The vitamin-status repletion layer
- Vitamin D3 to a 30–50 ng/mL 25-OH-D target if deficient — observational links to AMD risk; intervention data weaker.
- B vitamins if homocysteine is elevated — small trial data (Christen 2009) suggested B vitamin supplementation reduced AMD risk in women with cardiovascular risk; not a routine recommendation.
What to skip
- Beta-carotene supplementation in current or former smokers — the original AREDS formula used beta-carotene; the AREDS2 update substituted lutein/zeaxanthin specifically because of the lung cancer signal in former smokers. Use AREDS2-format products, not original AREDS, particularly if any smoking history.
- "Eye health" combination products with bilberry, eyebright, and unspecified herbal extracts — these typically include sub-therapeutic doses of AREDS2 ingredients plus uncharacterised botanicals; for confirmed AMD, use a USP-verified AREDS2 product instead.
- Mega-dose vitamin C or E alone — the AREDS2 doses are calibrated; chronic megadosing without the rest of the formula provides no additional benefit and can have other harms.
- "Astaxanthin for vision" claims — small signals in eye fatigue and accommodation in healthy adults; AMD-specific evidence is much weaker than AREDS2.
- CBD products marketed for AMD — no AMD-specific evidence; product variability and drug-interaction concerns.
What to track
This is an ophthalmology-led monitoring context. Standard follow-up includes regular dilated fundus exams, OCT imaging at intervals appropriate to AMD stage, and Amsler grid self-testing for early detection of conversion to wet AMD (sudden distortion or central scotoma warrants urgent ophthalmology review). Visual acuity tracking and contrast sensitivity tracking can be useful adjuncts at home.